The financials
Ligand Pharmaceuticals Incorporated by the numbers
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $64M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with net income of $49M (76% of revenue). For the full year FY2025, revenue was $268M (+60% year on year) and net income $124M. Its largest product in Q2 2026 was Material Sales Captisol at $8.0M, 12.2% of the disclosed total, just ahead of Contract Revenue And Income at 11.7%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $64M | $48M | +34% |
| Operating income | $8.6M | $8.4M | +1.7% |
| Net income | $49M | $4.8M | +901% |
| Diluted EPS | $2.22 | $0.24 | +825% |
| Product | Revenue | Share |
|---|---|---|
| Material Sales Captisol | $8.0M | 12% |
| Contract Revenue And Income | $7.7M | 12% |
| Contract Revenue And Other Income | $7.7M | 12% |
| Kyprolis | $7.0M | 11% |
| QARZIBA | $6.2M | 9.4% |
| Contract And Revenue Income Other | $5.0M | 7.6% |
| Royalty Intangible Other | $4.3M | 6.5% |
| Intangible Ohtuvayre | $4.1M | 6.3% |
| Financial Ohtuvayre Inventors | $3.3M | 5.0% |
| Rylaze | $3.2M | 4.9% |
| Contract | $2.7M | 4.1% |
| Capvaxive | $2.3M | 3.5% |
| Teriparatide Injection | $1.5M | 2.2% |
| Vaxneuvance | $1.4M | 2.1% |
| Financial Royalty Other | $1.2M | 1.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $65.5M (+61%)
Contract And Revenue Income Other grew +392% year on yearVaxneuvance -49% year on year
Segment Latestquarter on quarteryear on year
- Material Sales Captisol$8.0M$8.0MQoQ -7.8%year on year -3.7%-7.8%-3.7%
- Contract Revenue And Income$7.7M$7.7MQoQ +6885%year on year +161%+6885%+161%
- Contract Revenue And Other Income$7.7M$7.7MQoQ +6885%year on year +161%+6885%+161%
- Kyprolis$7.0M$7.0MQoQ +4.5%year on year -20%+4.5%-20%
- QARZIBA$6.2M$6.2MQoQ -2.4%year on year +4.5%-2.4%+4.5%
- Contract And Revenue Income Other$5.0M$5.0MQoQ -year on year +392%-+392%
- Royalty Intangible Other$4.3M$4.3MQoQ +14%year on year +66%+14%+66%
- Intangible Ohtuvayre$4.1M$4.1MQoQ +39%year on year +99%+39%+99%
- Financial Ohtuvayre Inventors$3.3M$3.3MQoQ +8.1%year on year -+8.1%-
- Rylaze$3.2M$3.2MQoQ -0.62%year on year +12%-0.62%+12%
- Contract$2.7M$2.7MQoQ +2339%year on year +39%+2339%+39%
- Capvaxive$2.3M$2.3MQoQ +18%year on year +2.9%+18%+2.9%
- Teriparatide Injection$1.5M$1.5MQoQ +11%year on year -36%+11%-36%
- Vaxneuvance$1.4M$1.4MQoQ -16%year on year -49%-16%-49%
- Financial Royalty Other$1.2M$1.2MQoQ +80%year on year +186%+80%+186%